N/A Completed N=615 Randomized Single-blind Screening

Hepatocellular Carcinoma Surveillance in Cirrhotics

Hepatocellular Carcinoma · Cirrhosis

Source: ClinicalTrials.gov NCT04248816 ↗

Enrolled (actual)

615

Serious AEs

—

Results posted

Feb 2023

Primary outcomePrimary: HCC Screening Completion — 27.6; 54.5; 54.1 Percentage of participants

Summary

This is a 3-arm pilot randomized controlled trial applying behavioral economic approaches (opt-out framing and financial incentives) to encourage patients with liver cirrhosis to complete regular surveillance ultrasounds which may allow for earlier diagnosis of and better outcomes for hepatocellular carcinoma (HCC).

Outcome Measures

Outcome	Result	p-value
PRIMARY HCC Screening Completion	27.6; 54.5; 54.1	—
SECONDARY HCC Screening Method	32.8; 59.4; 57.2	—

Eligibility Criteria

Inclusion Criteria

Patients who are 18+ years old
Current diagnosis of cirrhosis or advanced fibrosis
1 or more visits to a Penn Gastroenterology/Hepatology practice in the preceding two years
Currently followed by Penn Gastroenterology/Hepatology
Must live in the Philadelphia Metropolitan Statistical Area

Exclusion Criteria

History of HCC or other liver carcinoma diagnosis
History of liver transplant
Completed HCC screening within the past 7 months
Have a future screening scheduled
Have a different screening modality recommended by their physician (MRI, CT, etc.)
Patients with metastatic cancer
Patients receiving hospice care

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04248816). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.